Search

Your search keyword '"Lupus Nephritis chemically induced"' showing total 128 results

Search Constraints

Start Over You searched for: Descriptor "Lupus Nephritis chemically induced" Remove constraint Descriptor: "Lupus Nephritis chemically induced"
128 results on '"Lupus Nephritis chemically induced"'

Search Results

1. Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study.

2. Membranous lupus nephritis secondary to secukinumab therapy: A case report and literature review.

3. Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis.

4. Managing Lupus Nephritis in Children and Adolescents.

5. Rituximab as add-on therapy in patients with resistant lupus nephritis who have failed induction or maintenance therapy with other agents: A real-world experience from a single center in Mumbai.

6. Anti-complement factor H (CFH) autoantibodies could delay pristane-induced lupus nephritis.

7. Herpes zoster in lupus nephritis: experience on 292 patients followed up for 15 years.

8. Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine.

9. Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.

10. Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A "post-hoc" analysis of participants in the BLISS-LN and open label extension study belonging to a single center.

11. Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity.

12. Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta-analysis and a propensity score-matched case-control study.

13. Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial.

14. Belimumab for the treatment of pediatric patients with lupus nephritis.

15. Development of a novel Poly (I:C)-induced murine model with accelerated lupus nephritis and examination of the therapeutic effects of mycophenolate mofetil and a cathepsin S inhibitor.

16. Comparative Efficacy and Safety of Biological Agents in the Treatment of Lupus Nephritis: A Network Meta-Analysis.

17. [Efficacy and safety of half-dose rituximab in the treatment of 23 cases with lupus nephritis].

18. Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.

19. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.

20. Systemic lupus erythematosus following human papillomavirus vaccination: A case-based review.

21. First-line Combination Strategy Provides Favorable 5-year Outcomes for Patients with Lupus Nephritis: A Single-center Observational Study.

22. Multitarget therapy versus monotherapy as induction treatment for lupus nephritis: A meta-analysis of randomized controlled trials.

23. Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis.

24. Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy.

25. Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review.

26. Cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of Malaysian lupus nephritis patients.

27. Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton's Tyrosine Kinase.

28. Class II lupus nephritis with podocyte injury in imiquimod-induced lupus-prone mice.

29. Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis.

30. A pharmacoeconomic study comparing the use of mycophenolate mofetil or cyclophosphamide as induction therapy in lupus nephritis patients in Egypt.

31. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective.

32. Comparative Efficacy and Safety of Tacrolimus, Cyclosporin A, Mycophenolate Mofetil, Cyclophosphamide, and Corticosteroids as Induction Therapy for Membranous Lupus Nephritis: A Network Meta-Analysis.

33. 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivative attenuates lupus nephritis with less effect to thymocyte development.

34. Rapamycin alleviates renal damage in mice with systemic lupus erythematosus through improving immune response and function.

35. "Protenuria in SLE: Is it always lupus?"

36. Acute effects of air pollution on lupus nephritis in patients with systemic lupus erythematosus: A multicenter panel study in China.

37. Preclinical Testing of Viral Therapeutic Efficacy in Pristane-Induced Lupus Nephritis and Diffuse Alveolar Hemorrhage Mouse Models.

39. Lupus nephritis in a transgender woman on cross-sex hormone therapy: a case for the role of oestrogen in systemic lupus erythematosus.

40. α2AP is associated with the development of lupus nephritis through the regulation of plasmin inhibition and inflammatory responses.

41. Herbal medication triggering lupus nephritis - a case report.

42. Expression of XBP1s in B lymphocytes is critical for pristane-induced lupus nephritis in mice.

43. Low-dose 17α-ethinyl estradiol (EE) exposure exacerbates lupus renal disease and modulates immune responses to TLR7/9 agonists in genetically autoimmune-prone mice.

44. Retinoic Acid Exerts Disease Stage-Dependent Effects on Pristane-Induced Lupus.

45. α-mangostin attenuates pristane-induced lupus nephritis by regulating Th17 differentiation.

46. A Comparative Study on the Incidence, Aggravation, and Remission of Lupus Nephritis Based on iTRAQ Technology.

47. Dietary oleuropein and its new acyl-derivate attenuate murine lupus nephritis through HO-1/Nrf2 activation and suppressing JAK/STAT, NF-κB, MAPK and NLRP3 inflammasome signaling pathways.

48. Vasoactive intestinal peptide ameliorates renal injury in a pristane-induced lupus mouse model by modulating Th17/Treg balance.

49. Accelerated and Severe Lupus Nephritis Benefits From M1, an Active Metabolite of Ginsenoside, by Regulating NLRP3 Inflammasome and T Cell Functions in Mice.

50. Hydroxychloroquine-induced podocytopathy mimicking Fabry disease.

Catalog

Books, media, physical & digital resources